CIMARa
banner
cimaragroup.bsky.social
CIMARa
@cimaragroup.bsky.social
Consortium for Intracranial Metastasis Academic Research (CIMARa). Directors: Carey Anders, MD of Duke University and Hussein Tawbi, MD of MD Anderson.
Pinned
Curious about CIMARa and what we do? Read our white paper, recently published in Neuro-Oncology Advances! Physicians, researchers, and advocates focused on brain metastasis, including leptomeningeal disease, are welcome to join.
pubmed.ncbi.nlm.nih.gov/40276376/
Hello! Formally introducing CIMARa. Led by CareyAnders
(@dukemets.bsky.social) and @HTawbi_MD
(@mdanderson.bsky.social), we are physicians, scientists, non-profits & advocates who share the goal of improving outcomes for patients with #brainmets through awareness & coordination of research.
June 6, 2025 at 1:57 PM
Reposted by CIMARa
Metastatic brain tumors are different than primary brain tumors. Not only are they more common, they're not actually brain cancer. The cancer is still the primary cancer - lung, breast, or others - but that cancer is now in the brain.
June 6, 2025 at 1:03 PM
Reposted by CIMARa
Palliative care is about providing relief and preventing suffering at any age or stage of illness. Palliative care experts partner with patients, their families, and their medical teams to meet your personalized goals.
June 5, 2025 at 1:18 PM
Reposted by CIMARa
A recent study by DCBSM researchers found a nearly two-fold increase in the risk of radiation necrosis among patients with brain metastases receiving immunotherapies within four weeks of radiosurgery.

Learn more: neurosurgery.duke.edu/news/therapy...

#OncSky #MedSky #AcademicSky
June 4, 2025 at 12:57 PM
Reposted by CIMARa
LITT (laser interstitial thermal therapy) uses a laser to destroy unhealthy brain tissue, including new & recurrent brain tumors & radiation necrosis.

LITT is minimally invasive - the opening in the scalp is only about as big as a pencil eraser.

Learn more: www.dukehealth.org/treatments/n...
June 3, 2025 at 3:26 PM
Reposted by CIMARa
Did you know? Among patients with lung cancer, about 16-20 percent develop brain metastases. Risk of brain mets is highest in SCLC, EGFR, and ALK positive lung cancers.

#OncSky #MedSky
June 2, 2025 at 12:56 PM
Curious about CIMARa and what we do? Read our white paper, recently published in Neuro-Oncology Advances! Physicians, researchers, and advocates focused on brain metastasis, including leptomeningeal disease, are welcome to join.
pubmed.ncbi.nlm.nih.gov/40276376/
April 29, 2025 at 4:11 PM